Compare Davita Inc (DVA) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Fox Corp Class A — how do they compare? Davita Inc trades at $227.51 (market cap $14.92B), while Fox Corp Class A trades at $55.48 (market cap $21.85B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 1.02% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | FOXA | |
|---|---|---|
Market Cap | $14.92B | $21.85B |
Sector | Health | Media |
52-Week High | $235.71 | $76.11 |
52-Week Low | $103.87 | $48.79 |
Enterprise Value | $27.47B | $25.83B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FOXA trades at $55.9, up 3.29% today, with a bearish technical signal but strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $16.3B in 2025, with net income margin expanding to 13.88%. The company's acquisition of Roku for $22 billion marks a strategic pivot into streaming distribution, though it introduces leverage risk.
The outlook is mixed: analyst consensus targets $67.80 (21% upside) with a 50/50 buy/hold split, but 2026 forecasts show declining cash flow and earnings. Key risks include integration challenges from the Roku deal and streaming competition. Upside hinges on successful execution of the new strategy and advertising momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
